Nuclear Regulatory Commission May 9, 2019 – Federal Register Recent Federal Regulation Documents
Results 1 - 5 of 5
Information Collection: Criteria and Procedures for Determining Eligibility for Access to or Control Over Special Nuclear Material
The U.S. Nuclear Regulatory Commission (NRC) invites public comment on the renewal of Office of Management and Budget (OMB) approval for an existing collection of information. The information collection is entitled, ``Criteria and Procedures for Determining Eligibility for Access to or Control Over Special Nuclear Material.''
Information Collection: Rules of General Applicability to Domestic Licensing of Byproduct Material
The U.S. Nuclear Regulatory Commission (NRC) invites public comment on the renewal of Office of Management and Budget (OMB) approval for an existing collection of information. The information collection is entitled, ``10 CFR part 30, Rules of General Applicability to Domestic Licensing of Byproduct Material.''
Atomic Safety and Licensing Board; in the Matter of Powertech USA, Inc.; Dewey-Burdock in Situ Uranium Recovery Facility
The U.S. Nuclear Regulatory Commission (NRC) is issuing an Order to set a schedule for an evidentiary hearing in the Powertech USA, Inc., Dewey-Burdock In Situ Uranium Recovery Facility proceeding. The Order for Granting NRC Staff Motion and Scheduling Evidentiary Hearing became effective on April 29, 2019.
Advisory Committee on the Medical Uses of Isotopes: Meeting Notice
The U.S. Nuclear Regulatory Commission (NRC) will convene a teleconference meeting of the Advisory Committee on the Medical Uses of Isotopes (ACMUI) on June 10, 2019, to discuss: (1) The revisions to the ACMUI bylaws and (2) the draft report of the ACMUI Regulatory Guide 8.39 Subcommittee. This report will include the subcommittee's comments and recommendations on Phase 1 of the revisions to Regulatory Guide 8.39, ``Release of Patients Administered Radioactive Material.'' A phased approach is being conducted by the NRC staff to comprehensively update Regulatory Guide 8.39. Phase 1 of the revision provides licensees with more detailed instructions to patients before and after they have been administered radioactive material than what is currently provided in Regulatory Guide 8.39. Meeting information, including a copy of the agenda and handouts, will be available at https:// www.nrc.gov/reading-rm/doc-collections/acmui/meetings/2019.ht ml. The agenda and handouts may also be obtained by contacting Ms. Kellee Jamerson using the information below.
Program-Specific Guidance About Commercial Radiopharmacy Licenses
The U.S. Nuclear Regulatory Commission (NRC) has issued Revision 2 to NUREG-1556, Volume 13, ``Consolidated Guidance About Materials Licenses: Program-Specific Guidance About Commercial Radiopharmacy Licenses.'' Volume 13 of NUREG-1556 has been revised to include information on updated regulatory requirements, safety culture, security of radioactive materials, protection of sensitive information, and changes in regulatory policies and practices consistent with current regulations. This volume is intended for use by applicants, licensees, and the NRC staff.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
